Clostridium Diagnostics Market - Forecast(2024 - 2030)

Clostridium Diagnostics Market Overview

Clostridium Diagnostics Market size is estimated to reach $1.9 billion by 2027, growing at a CAGR of 7.3% during the forecast period 2022-2027. Clostridium is a gram-positive bacterium that can be found in a variety of forms. Disease-causing form of Clostridium bacteria which causes Clostridium difficile infection (CDI), a gastrointestinal ailment, frequently considered synonymous with antibiotic-associated diarrhea (AAD), is Clostridioides difficile. Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii cause gas gangrene, muscle necrosis, botulism, tetanus, pneumonia, endocarditis, arthritis and peritonitis. Frequent use of antibiotics leads to rapid multiplication of Clostridium difficile bacteria, owing to the absence of good microflora attributed to the effect of frequent consumption of antibiotics. However, antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems are used to cure the infection and fructooligosaccharides are proven to reduce the adhesion of clostridium. Various imaging modalities, including radiography, CT (Computed Tomography) and endoscopy, are used to diagnose this infection. Typical symptoms of Clostridium difficile include diarrhea, dehydration, fever, nausea, loss of appetite and weight loss. For the identification of Clostridium bacteria, monoclonal antibodies, DNA probes, differential light scattering, immunoassays, artificial intelligence, microcomputers & automation, flow cytometry, liposomes, MRI, chromatography and gel microdroplets are all potential diagnostic technologies. As per the Centers For Disease Control And Prevention (CDC), Clostridium perfringens bacteria are one of the most typical causes of foodborne illness (food poisoning) and these bacteria bring about almost 1 million illnesses in the U.S. every year. Almost 100 Clostridium species have been recognized. However, only 25 to 30 typically bring about human or animal ailment.

The increasing predominance of clostridium-related diseases and the growing population of the elderly are set to drive the Clostridium Diagnostics Industry. The surging technological progress expanded healthcare infrastructure and altered lifestyle of people are set to propel the growth of the Clostridium Diagnostics Market during the forecast period 2022-2027. This represents the Clostridium Diagnostics Industry Outlook.

Clostridium Diagnostics Market Report Coverage

The “Clostridium Diagnostics Market Report - Forecast (2022-2027)" by Industry ARC, covers an in-depth analysis of the following segments in the Clostridium Diagnostics Market.

Key Takeaways

• Geographically, North America Clostridium Diagnostics industry accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the advanced healthcare infrastructure in countries like U.S. and Canada in the North American region.
• Clostridium Diagnostics Market growth is being driven by the surging initiatives taken by the government like awareness programs to educate individuals and acceptance of portable point of care (POCT) products. However, the limited awareness regarding the test is one of the major factors hampering the growth of the Clostridium Diagnostics Market.
• Clostridium Diagnostics Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Clostridium Diagnostics Market report. 

Clostridium Diagnostics Market: Market Share (%) By Region, 2021

For More Details On this report - Request For Sample 

Clostridium Diagnostics Market Segment Analysis - by Testing Technology:

The Clostridium Diagnostics Market based on testing technology can be further segmented into Immunoassays, Molecular Diagnostics and Others. The Molecular Diagnostics Segment held the largest Clostridium Diagnostics market share in 2021. This growth is owing to the increased application of PCR technology in clinical diagnostics, rising demand for personalized and precision medicine and technological advances and applications in drug development. As per a research paper published in the National Library of Medicine in 2019, Real-time PCR for the diagnosis of toxic genes is the most effective diagnostic method for accurate and early diagnosis of Clostridium difficile infection. With the surging application of progressive molecular diagnostics and with the launch of commercially accessible tests, conventional diagnostic methods have been repeatedly substituted by the more novel rapid antigen detection and molecular-based techniques which are further propelling the growth of the Molecular Diagnostics segment.

Furthermore, the Immunoassays segment is estimated to grow with the fastest CAGR of 7.7% during the forecast period 2022-2027 owing to the rising prevalence of Clostridium-related diseases and the immunoassay technology offering an easy solution for diagnosis of Clostridium bacteria which is good to use in clinical laboratories and health centers.

Clostridium Diagnostics Market Segment Analysis - by End-Use:

The Clostridium Diagnostics Market based on end-use can be further segmented into Hospitals, Commercial Or Private Laboratories, Public Health Laboratories and Others. The Hospitals segment held the largest Clostridium Diagnostics market share in 2021. This growth is owing to the use of improved diagnostic technology over time in hospitals. The majority of hospitals have their own clinical laboratories or tie-up. In such clinical laboratories, the diagnostics of Clostridium is possible owing to the application of advanced techniques like immunoassay and molecular diagnostic technology in hospitals which is further propelling the growth of this segment. Furthermore, antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems are readily available in the hospital supporting the segment growth.

Furthermore, the Commercial Or Private Laboratories segment is estimated to grow with the fastest CAGR of 8.9% during the forecast period 2022-2027 owing to the increasing number of private diagnostic laboratories across the globe and reliable techniques used for diagnostic specific lab tests using fecal specimens with the application of these technologies showing higher results for clostridium detection. 

Clostridium Diagnostics Market Segment Analysis - by Geography:

The Clostridium Diagnostics Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Clostridium Diagnostics Market) held the largest Clostridium Diagnostics market share with 32% of the overall market in 2021. The growth of this region is owing to the well-established healthcare infrastructure, high expenditure on health and the continued prevalence of Clostridium in the North American region. According to the Centers For Disease Control And Prevention (CDC), nearly about 29000 patients died within 30 days after initial diagnosis of Clostridium difficile and more than 80% of deaths occurred in patients aged 65 years or older in America. More than 4.8 billion costs are borne by healthcare-associated infections every year in the U.S. As per the many research activities and studies conducted on Clostridioides difficile infection (CDI), most of all CDI are community associated with a mean incidence rate of 20 -30 per 100000 population. The increasing prevalence of Clostridioides difficile infection (CDI) coupled with the availability of antibiotics like benzylpenicillin, sulfonamides, tetracyclines, metronidazole, vancomycin and carbapenems is further fuelling the growth of the Clostridium Diagnostics Market size in the North American region.

Furthermore, the Europe region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like Europe being a developed region with the best healthcare and infrastructure facilities. However, the prevalence of clostridium is very high in the European region. As per European Center for Disease Prevention and Control, the annual burden of healthcare-associated with CDI was 123997 per year. Also, the number of deaths directly associated with CDI was 3700 per year as observed every year. The continuous outbreak of clostridium is further fuelling the progress of the Clostridium Diagnostics Market size in the European region.